Three Times Daily Dosing of UT-15C

United Therapeutics

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: UT-15C

Study type: Interventional

Funder types: Industry

Identifiers

NCT01746485

TDE-DU-102

Details and patient eligibility

About

To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers

Enrollment: 19 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

• Healthy male and female subjects
• aged 18-55 years of age;
• weight between 50 and 100 kg, with a body mass index (BMI) between 19.0 and 29.9 kg/m2, inclusive for female subjects and
• weight between 50 and 120 kg, with a BMI between 19.0 and 32.0 kg/m², inclusive for male subjects.

Trial design

19 participants in 1 patient group

UT-15C

Experimental group

Treatment:

Drug: UT-15C